SCHEMBL30837890

SCHEMBL30837890

CNC(=O)COc1ccc(Cn2c(=O)c3cc(OC(CF)CF)ccc3n(C3CCN(C=O)CC3)c2=O)cc1OC

nearest known ligand 0.83

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 10/20 0.83
PDE7B Q9NP56 5/20 0.83
PDE8A O60658 3/20 0.83
OPRL1 P41146 5/20 0.40
OPRM1 P35372 4/20 0.40
OPRD1 P41143 1/20 0.38
KCNH2 Q12809 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 3/20 0.36
MEN1 O00255 2/20 0.36
MAPK1 P28482 2/20 0.36
KMT2A Q03164 2/20 0.36
GAA P10253 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
TP53 P04637 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL100225 1.00 PDE7A (0.83) PDE7APDE7BPDE8AOPRL1OPRM1
SCHEMBL32681332 0.91 PDE7A (0.70) PDE7APDE7BPDE8AOPRL1OPRM1
SCHEMBL100822 0.91 PDE7A (0.70) PDE7APDE7BPDE8AOPRL1OPRM1
SCHEMBL30837881 0.91 PDE7A (1.00) PDE7APDE7BPDE8AOPRL1OPRM1
SCHEMBL100704 0.91 PDE7A (1.00) PDE7APDE7BPDE8AOPRL1OPRM1
SCHEMBL100171 0.90 PDE7A (0.90) PDE7APDE7BPDE8AOPRL1OPRM1
SCHEMBL30837889 0.90 PDE7A (0.86) PDE7APDE7BPDE8AOPRL1OPRM1
SCHEMBL100109 0.90 PDE7A (0.86) PDE7APDE7BPDE8AOPRL1OPRM1
SCHEMBL100224 0.90 PDE7A (0.89) PDE7APDE7BPDE8AOPRL1OPRM1
SCHEMBL100957 0.89 PDE7A (1.00) PDE7APDE7BPDE8ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260060970-A1 Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance MITODICURE GMBH (DE) 2026-03-05 US disclosed
EP-4572765-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE Mitodicure GmbH (DE) 2025-06-25 EP disclosed
WO-2024038089-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE MITODICURE GMBH (DE) 2024-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260060970-A1 Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance PDE5A, PDE4C, PDE12 PDE7A 5/4885PDE7B 14/4885PDE8A 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.